EMEA (Europe, Middle East and Africa) RNA Interference (RNAi) Drug Delivery Market Report 2017

July 2017 | 118 pages | ID: EDCDC272AABEN
QYResearch

Abstracts

In this report, the EMEA RNA Interference (RNAi) Drug Delivery market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of RNA Interference (RNAi) Drug Delivery for these regions, from 2012 to 2022 (forecast)

• Europe: Germany, France, UK, Russia, Italy and Benelux;
• Middle East: Saudi Arabia, Israel, UAE and Iran;
• Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA RNA Interference (RNAi) Drug Delivery market competition by top manufacturers/players, with RNA Interference (RNAi) Drug Delivery sales volume (K Units), price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including

• Metabolic disorders
• Alnylam Pharmaceuticals Inc
• Merck & Co. Inc
• Access Pharmaceuticals Inc
• Dicerna Pharmaceuticals Inc
• Calondo Pharmaceuticals Inc
• Marina Biotech Inc
• RXi Pharmaceuticals Corp
• Quark Pharmaceuticals Inc
• Silence Therapeutics plc
• Tacere Therapeutics Inc
• PhaseRx Inc
• Sirnaomics Inc
• Traversa Therapeutics Inc

On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into

• Nanoparticle Drug Delivery Technology
• Pulmonary Drug Delivery Technology
• Nucleic Acid Drug Delivery Technology
• Aptamer Drug Delivery Technology

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of RNA Interference (RNAi) Drug Delivery for each application, including

• Infectious Diseases
• Cardiology
• Oncology
• Neurology
• Ophthalmology
• Metabolic Disorders

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

EMEA (Europe, Middle East and Africa) RNA Interference (RNAi) Drug Delivery Market Report 2017

1 RNA INTERFERENCE (RNAI) DRUG DELIVERY OVERVIEW

1.1 Product Overview and Scope of RNA Interference (RNAi) Drug Delivery
1.2 Classification of RNA Interference (RNAi) Drug Delivery
  1.2.1 EMEA RNA Interference (RNAi) Drug Delivery Market Size (Sales) Comparison by Type (2012-2022)
  1.2.2 EMEA RNA Interference (RNAi) Drug Delivery Market Size (Sales) Market Share by Type (Product Category) in 2016
  1.2.3 Nanoparticle Drug Delivery Technology
  1.2.4 Pulmonary Drug Delivery Technology
  1.2.5 Nucleic Acid Drug Delivery Technology
  1.2.6 Aptamer Drug Delivery Technology
1.3 EMEA RNA Interference (RNAi) Drug Delivery Market by Application/End Users
  1.3.1 EMEA RNA Interference (RNAi) Drug Delivery Sales (Volume) and Market Share Comparison by Application (2012-2022
  1.3.2 Infectious Diseases
  1.3.3 Cardiology
  1.3.4 Oncology
  1.3.5 Neurology
  1.3.6 Ophthalmology
  1.3.7 Metabolic Disorders
1.4 EMEA RNA Interference (RNAi) Drug Delivery Market by Region
  1.4.1 EMEA RNA Interference (RNAi) Drug Delivery Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 Europe Status and Prospect (2012-2022)
  1.4.3 Middle East Status and Prospect (2012-2022)
  1.4.4 Africa Status and Prospect (2012-2022)
1.5 EMEA Market Size (Value and Volume) of RNA Interference (RNAi) Drug Delivery (2012-2022)
  1.5.1 EMEA RNA Interference (RNAi) Drug Delivery Sales and Growth Rate (2012-2022)
  1.5.2 EMEA RNA Interference (RNAi) Drug Delivery Revenue and Growth Rate (2012-2022)

2 EMEA RNA INTERFERENCE (RNAI) DRUG DELIVERY COMPETITION BY MANUFACTURERS/PLAYERS/SUPPLIERS, REGION, TYPE AND APPLICATION

2.1 EMEA RNA Interference (RNAi) Drug Delivery Market Competition by Players/Manufacturers
  2.1.1 EMEA RNA Interference (RNAi) Drug Delivery Sales Volume and Market Share of Major Players (2012-2017)
  2.1.2 EMEA RNA Interference (RNAi) Drug Delivery Revenue and Share by Players (2012-2017)
  2.1.3 EMEA RNA Interference (RNAi) Drug Delivery Sale Price by Players (2012-2017)
2.2 EMEA RNA Interference (RNAi) Drug Delivery (Volume and Value) by Type/Product Category
  2.2.1 EMEA RNA Interference (RNAi) Drug Delivery Sales and Market Share by Type (2012-2017)
  2.2.2 EMEA RNA Interference (RNAi) Drug Delivery Revenue and Market Share by Type (2012-2017)
  2.2.3 EMEA RNA Interference (RNAi) Drug Delivery Sale Price by Type (2012-2017)
2.3 EMEA RNA Interference (RNAi) Drug Delivery (Volume) by Application
2.4 EMEA RNA Interference (RNAi) Drug Delivery (Volume and Value) by Region
  2.4.1 EMEA RNA Interference (RNAi) Drug Delivery Sales and Market Share by Region (2012-2017)
  2.4.2 EMEA RNA Interference (RNAi) Drug Delivery Revenue and Market Share by Region (2012-2017)
  2.4.3 EMEA RNA Interference (RNAi) Drug Delivery Sales Price by Region (2012-2017)

3 EUROPE RNA INTERFERENCE (RNAI) DRUG DELIVERY (VOLUME, VALUE AND SALES PRICE), BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

3.1 Europe RNA Interference (RNAi) Drug Delivery Sales and Value (2012-2017)
  3.1.1 Europe RNA Interference (RNAi) Drug Delivery Sales Volume and Growth Rate (2012-2017)
  3.1.2 Europe RNA Interference (RNAi) Drug Delivery Revenue and Growth Rate (2012-2017)
3.2 Europe RNA Interference (RNAi) Drug Delivery Sales and Market Share by Type
3.3 Europe RNA Interference (RNAi) Drug Delivery Sales and Market Share by Application
3.4 Europe RNA Interference (RNAi) Drug Delivery Sales Volume and Value (Revenue) by Countries
  3.4.1 Europe RNA Interference (RNAi) Drug Delivery Sales Volume by Countries (2012-2017)
  3.4.2 Europe RNA Interference (RNAi) Drug Delivery Revenue by Countries (2012-2017)
  3.4.3 Germany RNA Interference (RNAi) Drug Delivery Sales and Growth Rate (2012-2017)
  3.4.4 France RNA Interference (RNAi) Drug Delivery Sales and Growth Rate (2012-2017)
  3.4.5 UK RNA Interference (RNAi) Drug Delivery Sales and Growth Rate (2012-2017)
  3.4.6 Russia RNA Interference (RNAi) Drug Delivery Sales and Growth Rate (2012-2017)
  3.4.7 Italy RNA Interference (RNAi) Drug Delivery Sales and Growth Rate (2012-2017)
  3.4.8 Benelux RNA Interference (RNAi) Drug Delivery Sales and Growth Rate (2012-2017)

4 MIDDLE EAST RNA INTERFERENCE (RNAI) DRUG DELIVERY (VOLUME, VALUE AND SALES PRICE), BY REGION, TYPE AND APPLICATION

4.1 Middle East RNA Interference (RNAi) Drug Delivery Sales and Value (2012-2017)
  4.1.1 Middle East RNA Interference (RNAi) Drug Delivery Sales Volume and Growth Rate (2012-2017)
  4.1.2 Middle East RNA Interference (RNAi) Drug Delivery Revenue and Growth Rate (2012-2017)
4.2 Middle East RNA Interference (RNAi) Drug Delivery Sales and Market Share by Type
4.3 Middle East RNA Interference (RNAi) Drug Delivery Sales and Market Share by Application
4.4 Middle East RNA Interference (RNAi) Drug Delivery Sales Volume and Value (Revenue) by Countries
  4.4.1 Middle East RNA Interference (RNAi) Drug Delivery Sales Volume by Countries (2012-2017)
  4.4.2 Middle East RNA Interference (RNAi) Drug Delivery Revenue by Countries (2012-2017)
  4.4.3 Saudi Arabia RNA Interference (RNAi) Drug Delivery Sales and Growth Rate (2012-2017)
  4.4.4 Israel RNA Interference (RNAi) Drug Delivery Sales and Growth Rate (2012-2017)
  4.4.5 UAE RNA Interference (RNAi) Drug Delivery Sales and Growth Rate (2012-2017)
  4.4.6 Iran RNA Interference (RNAi) Drug Delivery Sales and Growth Rate (2012-2017)

5 AFRICA RNA INTERFERENCE (RNAI) DRUG DELIVERY (VOLUME, VALUE AND SALES PRICE) BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

5.1 Africa RNA Interference (RNAi) Drug Delivery Sales and Value (2012-2017)
  5.1.1 Africa RNA Interference (RNAi) Drug Delivery Sales Volume and Growth Rate (2012-2017)
  5.1.2 Africa RNA Interference (RNAi) Drug Delivery Revenue and Growth Rate (2012-2017)
5.2 Africa RNA Interference (RNAi) Drug Delivery Sales and Market Share by Type
5.3 Africa RNA Interference (RNAi) Drug Delivery Sales and Market Share by Application
5.4 Africa RNA Interference (RNAi) Drug Delivery Sales Volume and Value (Revenue) by Countries
  5.4.1 Africa RNA Interference (RNAi) Drug Delivery Sales Volume by Countries (2012-2017)
  5.4.2 Africa RNA Interference (RNAi) Drug Delivery Revenue by Countries (2012-2017)
  5.4.3 South Africa RNA Interference (RNAi) Drug Delivery Sales and Growth Rate (2012-2017)
  5.4.4 Nigeria RNA Interference (RNAi) Drug Delivery Sales and Growth Rate (2012-2017)
  5.4.5 Egypt RNA Interference (RNAi) Drug Delivery Sales and Growth Rate (2012-2017)
  5.4.6 Algeria RNA Interference (RNAi) Drug Delivery Sales and Growth Rate (2012-2017)

6 EMEA RNA INTERFERENCE (RNAI) DRUG DELIVERY MANUFACTURERS/PLAYERS PROFILES AND SALES DATA

6.1 Metabolic disorders
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 RNA Interference (RNAi) Drug Delivery Product Type, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Metabolic disorders RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Alnylam Pharmaceuticals Inc
  6.2.1 Company Basic Information, Manufacturing Base and Competitors
  6.2.2 RNA Interference (RNAi) Drug Delivery Product Type, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Alnylam Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Merck & Co. Inc
  6.3.1 Company Basic Information, Manufacturing Base and Competitors
  6.3.2 RNA Interference (RNAi) Drug Delivery Product Type, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Merck & Co. Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Access Pharmaceuticals Inc
  6.4.1 Company Basic Information, Manufacturing Base and Competitors
  6.4.2 RNA Interference (RNAi) Drug Delivery Product Type, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Access Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Dicerna Pharmaceuticals Inc
  6.5.1 Company Basic Information, Manufacturing Base and Competitors
  6.5.2 RNA Interference (RNAi) Drug Delivery Product Type, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Dicerna Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Calondo Pharmaceuticals Inc
  6.6.1 Company Basic Information, Manufacturing Base and Competitors
  6.6.2 RNA Interference (RNAi) Drug Delivery Product Type, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Calondo Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Marina Biotech Inc
  6.7.1 Company Basic Information, Manufacturing Base and Competitors
  6.7.2 RNA Interference (RNAi) Drug Delivery Product Type, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Marina Biotech Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 RXi Pharmaceuticals Corp
  6.8.1 Company Basic Information, Manufacturing Base and Competitors
  6.8.2 RNA Interference (RNAi) Drug Delivery Product Type, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 RXi Pharmaceuticals Corp RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Quark Pharmaceuticals Inc
  6.9.1 Company Basic Information, Manufacturing Base and Competitors
  6.9.2 RNA Interference (RNAi) Drug Delivery Product Type, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Quark Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Silence Therapeutics plc
  6.10.1 Company Basic Information, Manufacturing Base and Competitors
  6.10.2 RNA Interference (RNAi) Drug Delivery Product Type, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Silence Therapeutics plc RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview
6.11 Tacere Therapeutics Inc
6.12 PhaseRx Inc
6.13 Sirnaomics Inc
6.14 Traversa Therapeutics Inc

7 RNA INTERFERENCE (RNAI) DRUG DELIVERY MANUFACTURING COST ANALYSIS

7.1 RNA Interference (RNAi) Drug Delivery Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of RNA Interference (RNAi) Drug Delivery

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 RNA Interference (RNAi) Drug Delivery Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of RNA Interference (RNAi) Drug Delivery Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 EMEA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET FORECAST (2017-2022)

11.1 EMEA RNA Interference (RNAi) Drug Delivery Sales, Revenue and Price Forecast (2017-2022)
  11.1.1 EMEA RNA Interference (RNAi) Drug Delivery Sales and Growth Rate Forecast (2017-2022)
  11.1.2 EMEA RNA Interference (RNAi) Drug Delivery Revenue and Growth Rate Forecast (2017-2022)
  11.1.3 EMEA RNA Interference (RNAi) Drug Delivery Price and Trend Forecast (2017-2022)
11.2 EMEA RNA Interference (RNAi) Drug Delivery Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.3 Europe RNA Interference (RNAi) Drug Delivery Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.4 Middle Eastt RNA Interference (RNAi) Drug Delivery Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.5 Africa RNA Interference (RNAi) Drug Delivery Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.6 EMEA RNA Interference (RNAi) Drug Delivery Sales Forecast by Type (2017-2022)
11.7 EMEA RNA Interference (RNAi) Drug Delivery Sales Forecast by Application (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of RNA Interference (RNAi) Drug Delivery
Figure EMEA RNA Interference (RNAi) Drug Delivery Sales Volume (K Units) by Type (2012-2022)
Figure EMEA RNA Interference (RNAi) Drug Delivery Sales Volume Market Share by Type (Product Category) in 2016
Figure Nanoparticle Drug Delivery Technology Product Picture
Figure Pulmonary Drug Delivery Technology Product Picture
Figure Nucleic Acid Drug Delivery Technology Product Picture
Figure Aptamer Drug Delivery Technology Product Picture
Figure EMEA RNA Interference (RNAi) Drug Delivery Sales Volume (K Units) by Application (2012-2022)
Figure EMEA Sales Market Share of RNA Interference (RNAi) Drug Delivery by Application in 2016
Figure Infectious Diseases Examples
Table Key Downstream Customer in Infectious Diseases
Figure Cardiology Examples
Table Key Downstream Customer in Cardiology
Figure Oncology Examples
Table Key Downstream Customer in Oncology
Figure Neurology Examples
Table Key Downstream Customer in Neurology
Figure Ophthalmology Examples
Table Key Downstream Customer in Ophthalmology
Figure Metabolic Disorders Examples
Table Key Downstream Customer in Metabolic Disorders
Figure EMEA RNA Interference (RNAi) Drug Delivery Market Size (Million USD) by Region (2012-2022)
Figure Europe RNA Interference (RNAi) Drug Delivery Revenue (Million USD) and Growth Rate (2012-2022)
Figure Europe RNA Interference (RNAi) Drug Delivery Revenue (Million USD) Status and Forecast by Countries
Figure Middle East RNA Interference (RNAi) Drug Delivery Revenue (Million USD) and Growth Rate (2012-2022)
Figure Middle East RNA Interference (RNAi) Drug Delivery Revenue (Million USD) Status and Forecast by Countries
Figure Africa RNA Interference (RNAi) Drug Delivery Revenue (Million USD) and Growth Rate (2012-2022)
Figure Africa RNA Interference (RNAi) Drug Delivery Revenue (Million USD) Status and Forecast by Countries
Figure EMEA RNA Interference (RNAi) Drug Delivery Sales Volume and Growth Rate (2012-2022)
Figure EMEA RNA Interference (RNAi) Drug Delivery Revenue (Million USD) and Growth Rate (2012-2022)
Figure EMEA RNA Interference (RNAi) Drug Delivery Market Major Players Product Sales Volume (K Units) (2012-2017)
Table EMEA RNA Interference (RNAi) Drug Delivery Sales Volume (K Units) of Major Players (2012-2017)
Table EMEA RNA Interference (RNAi) Drug Delivery Sales Share by Players (2012-2017)
Figure 2016 RNA Interference (RNAi) Drug Delivery Sales Share by Players
Figure 2017 RNA Interference (RNAi) Drug Delivery Sales Share by Players
Figure EMEA RNA Interference (RNAi) Drug Delivery Market Major Players Product Revenue (Million USD) (2012-2017)
Table EMEA RNA Interference (RNAi) Drug Delivery Revenue (Million USD) by Players (2012-2017)
Table EMEA RNA Interference (RNAi) Drug Delivery Revenue Share by Players (2012-2017)
Table 2016 EMEA RNA Interference (RNAi) Drug Delivery Revenue Share by Players
Table 2017 EMEA RNA Interference (RNAi) Drug Delivery Revenue Share by Players
Table EMEA RNA Interference (RNAi) Drug Delivery Sale Price (USD/Unit) by Players (2012-2017)
Table EMEA RNA Interference (RNAi) Drug Delivery Sales (K Units) and Market Share by Type (2012-2017)
Table EMEA RNA Interference (RNAi) Drug Delivery Sales Share by Type (2012-2017)
Figure Sales Market Share of RNA Interference (RNAi) Drug Delivery by Type (2012-2017)
Figure EMEA RNA Interference (RNAi) Drug Delivery Sales Market Share by Type (2012-2017)
Table EMEA RNA Interference (RNAi) Drug Delivery Revenue (Million USD) and Market Share by Type (2012-2017)
Table EMEA RNA Interference (RNAi) Drug Delivery Revenue Share by Type (2012-2017)
Figure Revenue Market Share of RNA Interference (RNAi) Drug Delivery by Type in 2016
Table EMEA RNA Interference (RNAi) Drug Delivery Sale Price (USD/Unit) by Type (2012-2017)
Table EMEA RNA Interference (RNAi) Drug Delivery Sales (K Units) and Market Share by Application (2012-2017)
Table EMEA RNA Interference (RNAi) Drug Delivery Sales Share by Application (2012-2017)
Figure Sales Market Share of RNA Interference (RNAi) Drug Delivery by Application (2012-2017)
Figure EMEA RNA Interference (RNAi) Drug Delivery Sales Market Share by Application in 2016
Table EMEA RNA Interference (RNAi) Drug Delivery Sales (K Units) and Market Share by Region (2012-2017)
Table EMEA RNA Interference (RNAi) Drug Delivery Sales Share by Region (2012-2017)
Figure Sales Market Share of RNA Interference (RNAi) Drug Delivery by Region (2012-2017)
Figure EMEA RNA Interference (RNAi) Drug Delivery Sales Market Share in 2016
Table EMEA RNA Interference (RNAi) Drug Delivery Revenue (Million USD) and Market Share by Region (2012-2017)
Table EMEA RNA Interference (RNAi) Drug Delivery Revenue Share by Region (2012-2017)
Figure Revenue Market Share of RNA Interference (RNAi) Drug Delivery by Region (2012-2017)
Figure EMEA RNA Interference (RNAi) Drug Delivery Revenue Market Share Regions in 2016
Table EMEA RNA Interference (RNAi) Drug Delivery Sales Price (USD/Unit) by Region (2012-2017)
Figure Europe RNA Interference (RNAi) Drug Delivery Sales (K Units) and Growth Rate (2012-2017)
Figure Europe RNA Interference (RNAi) Drug Delivery Revenue and Growth Rate (2012-2017)
Table Europe RNA Interference (RNAi) Drug Delivery Sales (K Units) by Type (2012-2017)
Table Europe RNA Interference (RNAi) Drug Delivery Market Share by Type (2012-2017)
Figure Europe RNA Interference (RNAi) Drug Delivery Market Share by Type in 2016
Table Europe RNA Interference (RNAi) Drug Delivery Sales (K Units) by Application (2012-2017)
Table Europe RNA Interference (RNAi) Drug Delivery Market Share by Application (2012-2017)
Figure Europe RNA Interference (RNAi) Drug Delivery Market Share by Application in 2016
Table Europe RNA Interference (RNAi) Drug Delivery Sales (K Units) by Countries (2012-2017)
Table Europe RNA Interference (RNAi) Drug Delivery Sales Market Share by Countries (2012-2017)
Figure Europe RNA Interference (RNAi) Drug Delivery Sales Market Share by Countries (2012-2017)
Figure Europe RNA Interference (RNAi) Drug Delivery Sales Market Share by Countries in 2016
Table Europe RNA Interference (RNAi) Drug Delivery Revenue (Million USD) by Countries (2012-2017)
Table Europe RNA Interference (RNAi) Drug Delivery Revenue Market Share by Countries (2012-2017)
Figure Europe RNA Interference (RNAi) Drug Delivery Revenue Market Share by Countries (2012-2017)
Figure Europe RNA Interference (RNAi) Drug Delivery Revenue Market Share by Countries in 2016
Figure Germany RNA Interference (RNAi) Drug Delivery Sales (K Units) and Growth Rate (2012-2017)
Figure France RNA Interference (RNAi) Drug Delivery Sales (K Units) and Growth Rate (2012-2017)
Figure UK RNA Interference (RNAi) Drug Delivery Sales (K Units) and Growth Rate (2012-2017)
Figure Russia RNA Interference (RNAi) Drug Delivery Sales (K Units) and Growth Rate (2012-2017)
Figure Italy RNA Interference (RNAi) Drug Delivery Sales (K Units) and Growth Rate (2012-2017)
Figure Benelux RNA Interference (RNAi) Drug Delivery Sales (K Units) and Growth Rate (2012-2017)
Figure Middle East RNA Interference (RNAi) Drug Delivery Sales (K Units) and Growth Rate (2012-2017)
Figure Middle East RNA Interference (RNAi) Drug Delivery Revenue (Million USD) and Growth Rate (2012-2017)
Table Middle East RNA Interference (RNAi) Drug Delivery Sales (K Units) by Type (2012-2017)
Table Middle East RNA Interference (RNAi) Drug Delivery Market Share by Type (2012-2017)
Figure Middle East RNA Interference (RNAi) Drug Delivery Market Share by Type (2012-2017)
Table Middle East RNA Interference (RNAi) Drug Delivery Sales (K Units) by Applications (2012-2017)
Table Middle East RNA Interference (RNAi) Drug Delivery Market Share by Applications (2012-2017)
Figure Middle East RNA Interference (RNAi) Drug Delivery Sales Market Share by Application in 2016
Table Middle East RNA Interference (RNAi) Drug Delivery Sales Volume (K Units) by Countries (2012-2017)
Table Middle East RNA Interference (RNAi) Drug Delivery Sales Volume Market Share by Countries (2012-2017)
Figure Middle East RNA Interference (RNAi) Drug Delivery Sales Volume Market Share by Countries in 2016
Table Middle East RNA Interference (RNAi) Drug Delivery Revenue (Million USD) by Countries (2012-2017)
Table Middle East RNA Interference (RNAi) Drug Delivery Revenue Market Share by Countries (2012-2017)
Figure Middle East RNA Interference (RNAi) Drug Delivery Revenue Market Share by Countries (2012-2017)
Figure Middle East RNA Interference (RNAi) Drug Delivery Revenue Market Share by Countries in 2016
Figure Saudi Arabia RNA Interference (RNAi) Drug Delivery Sales (K Units) and Growth Rate (2012-2017)
Figure Israel RNA Interference (RNAi) Drug Delivery Sales (K Units) and Growth Rate (2012-2017)
Figure UAE RNA Interference (RNAi) Drug Delivery Sales (K Units) and Growth Rate (2012-2017)
Figure Iran RNA Interference (RNAi) Drug Delivery Sales (K Units) and Growth Rate (2012-2017)
Figure Africa RNA Interference (RNAi) Drug Delivery Sales (K Units) and Growth Rate (2012-2017)
Figure Africa RNA Interference (RNAi) Drug Delivery Revenue (Million USD) and Growth Rate (2012-2017)
Table Africa RNA Interference (RNAi) Drug Delivery Sales (K Units) by Type (2012-2017)
Table Africa RNA Interference (RNAi) Drug Delivery Sales Market Share by Type (2012-2017)
Figure Africa RNA Interference (RNAi) Drug Delivery Sales Market Share by Type (2012-2017)
Figure Africa RNA Interference (RNAi) Drug Delivery Sales Market Share by Type in 2016
Table Africa RNA Interference (RNAi) Drug Delivery Sales (K Units) by Application (2012-2017)
Table Africa RNA Interference (RNAi) Drug Delivery Sales Market Share by Application (2012-2017)
Figure Africa RNA Interference (RNAi) Drug Delivery Sales Market Share by Application (2012-2017)
Table Africa RNA Interference (RNAi) Drug Delivery Sales Volume (K Units) by Countries (2012-2017)
Table Africa RNA Interference (RNAi) Drug Delivery Sales Market Share by Countries (2012-2017)
Figure Africa RNA Interference (RNAi) Drug Delivery Sales Market Share by Countries (2012-2017)
Figure Africa RNA Interference (RNAi) Drug Delivery Sales Market Share by Countries in 2016
Table Africa RNA Interference (RNAi) Drug Delivery Revenue (Million USD) by Countries (2012-2017)
Table Africa RNA Interference (RNAi) Drug Delivery Revenue Market Share by Countries (2012-2017)
Figure Africa RNA Interference (RNAi) Drug Delivery Revenue Market Share by Countries (2012-2017)
Figure Africa RNA Interference (RNAi) Drug Delivery Revenue Market Share by Countries in 2016
Figure South Africa RNA Interference (RNAi) Drug Delivery Sales (K Units) and Growth Rate (2012-2017)
Figure Nigeria RNA Interference (RNAi) Drug Delivery Sales (K Units) and Growth Rate (2012-2017)
Figure Egypt RNA Interference (RNAi) Drug Delivery Sales (K Units) and Growth Rate (2012-2017)
Figure Algeria RNA Interference (RNAi) Drug Delivery Sales (K Units) and Growth Rate (2012-2017)
Table Metabolic disorders RNA Interference (RNAi) Drug Delivery Basic Information List
Table Metabolic disorders RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Metabolic disorders RNA Interference (RNAi) Drug Delivery Sales (K Units) and Growth Rate (2012-2017)
Figure Metabolic disorders RNA Interference (RNAi) Drug Delivery Sales Market Share in EMEA (2012-2017)
Figure Metabolic disorders RNA Interference (RNAi) Drug Delivery Revenue Market Share in EMEA (2012-2017)
Table Alnylam Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Basic Information List
Table Alnylam Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Alnylam Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units) and Growth Rate (2012-2017)
Figure Alnylam Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales Market Share in EMEA (2012-2017)
Figure Alnylam Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Revenue Market Share in EMEA (2012-2017)
Table Merck & Co. Inc RNA Interference (RNAi) Drug Delivery Basic Information List
Table Merck & Co. Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Merck & Co. Inc RNA Interference (RNAi) Drug Delivery Sales (K Units) and Growth Rate (2012-2017)
Figure Merck & Co. Inc RNA Interference (RNAi) Drug Delivery Sales Market Share in EMEA (2012-2017)
Figure Merck & Co. Inc RNA Interference (RNAi) Drug Delivery Revenue Market Share in EMEA (2012-2017)
Table Access Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Basic Information List
Table Access Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Access Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units) and Growth Rate (2012-2017)
Figure Access Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales Market Share in EMEA (2012-2017)
Figure Access Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Revenue Market Share in EMEA (2012-2017)
Table Dicerna Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Basic Information List
Table Dicerna Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Dicerna Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units) and Growth Rate (2012-2017)
Figure Dicerna Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales Market Share in EMEA (2012-2017)
Figure Dicerna Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Revenue Market Share in EMEA (2012-2017)
Table Calondo Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Basic Information List
Table Calondo Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Calondo Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units) and Growth Rate (2012-2017)
Figure Calondo Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales Market Share in EMEA (2012-2017)
Figure Calondo Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Revenue Market Share in EMEA (2012-2017)
Table Marina Biotech Inc RNA Interference (RNAi) Drug Delivery Basic Information List
Table Marina Biotech Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Marina Biotech Inc RNA Interference (RNAi) Drug Delivery Sales (K Units) and Growth Rate (2012-2017)
Figure Marina Biotech Inc RNA Interference (RNAi) Drug Delivery Sales Market Share in EMEA (2012-2017)
Figure Marina Biotech Inc RNA Interference (RNAi) Drug Delivery Revenue Market Share in EMEA (2012-2017)
Table RXi Pharmaceuticals Corp RNA Interference (RNAi) Drug Delivery Basic Information List
Table RXi Pharmaceuticals Corp RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure RXi Pharmaceuticals Corp RNA Interference (RNAi) Drug Delivery Sales (K Units) and Growth Rate (2012-2017)
Figure RXi Pharmaceuticals Corp RNA Interference (RNAi) Drug Delivery Sales Market Share in EMEA (2012-2017)
Figure RXi Pharmaceuticals Corp RNA Interference (RNAi) Drug Delivery Revenue Market Share in EMEA (2012-2017)
Table Quark Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Basic Information List
Table Quark Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Quark Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units) and Growth Rate (2012-2017)
Figure Quark Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales Market Share in EMEA (2012-2017)
Figure Quark Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Revenue Market Share in EMEA (2012-2017)
Table Silence Therapeutics plc RNA Interference (RNAi) Drug Delivery Basic Information List
Table Silence Therapeutics plc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Silence Therapeutics plc RNA Interference (RNAi) Drug Delivery Sales (K Units) and Growth Rate (2012-2017)
Figure Silence Therapeutics plc RNA Interference (RNAi) Drug Delivery Sales Market Share in EMEA (2012-2017)
Figure Silence Therapeutics plc RNA Interference (RNAi) Drug Delivery Revenue Market Share in EMEA (2012-2017)
Table Tacere Therapeutics Inc RNA Interference (RNAi) Drug Delivery Basic Information List
Table PhaseRx Inc RNA Interference (RNAi) Drug Delivery Basic Information List
Table Sirnaomics Inc RNA Interference (RNAi) Drug Delivery Basic Information List
Table Traversa Therapeutics Inc RNA Interference (RNAi) Drug Delivery Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of RNA Interference (RNAi) Drug Delivery
Figure Manufacturing Process Analysis of RNA Interference (RNAi) Drug Delivery
Figure RNA Interference (RNAi) Drug Delivery Industrial Chain Analysis
Table Raw Materials Sources of RNA Interference (RNAi) Drug Delivery Major Manufacturers in 2016
Table Major Buyers of RNA Interference (RNAi) Drug Delivery
Table Distributors/Traders List
Figure EMEA RNA Interference (RNAi) Drug Delivery Sales (K Units) and Growth Rate Forecast (2017-2022)
Figure EMEA RNA Interference (RNAi) Drug Delivery Revenue and Growth Rate Forecast (2017-2022)
Figure EMEA RNA Interference (RNAi) Drug Delivery Price (USD/Unit) and Trend Forecast (2017-2022)
Table EMEA RNA Interference (RNAi) Drug Delivery Sales (K Units) Forecast by Region (2017-2022)
Figure EMEA RNA Interference (RNAi) Drug Delivery Sales Market Share Forecast by Region (2017-2022)
Table EMEA RNA Interference (RNAi) Drug Delivery Revenue (Million USD) Forecast by Region (2017-2022)
Figure EMEA RNA Interference (RNAi) Drug Delivery Revenue Market Share Forecast by Region (2017-2022)
Table Europe RNA Interference (RNAi) Drug Delivery Sales (K Units) Forecast by Countries (2017-2022)
Figure Europe RNA Interference (RNAi) Drug Delivery Sales Market Share Forecast by Countries (2017-2022)
Table Europe RNA Interference (RNAi) Drug Delivery Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Europe RNA Interference (RNAi) Drug Delivery Revenue Market Share Forecast by Countries (2017-2022)
Table Middle East RNA Interference (RNAi) Drug Delivery Sales (K Units) Forecast by Countries (2017-2022)
Figure Middle East RNA Interference (RNAi) Drug Delivery Sales Market Share Forecast by Countries (2017-2022)
Table Middle East RNA Interference (RNAi) Drug Delivery Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Middle East RNA Interference (RNAi) Drug Delivery Revenue Market Share Forecast by Countries (2017-2022)
Table Africa RNA Interference (RNAi) Drug Delivery Sales (K Units) Forecast by Countries (2017-2022)
Figure Africa RNA Interference (RNAi) Drug Delivery Sales Market Share Forecast by Countries (2017-2022)
Table Africa RNA Interference (RNAi) Drug Delivery Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Africa RNA Interference (RNAi) Drug Delivery Revenue Market Share Forecast by Countries (2017-2022)
Table EMEA RNA Interference (RNAi) Drug Delivery Sales (K Units) Forecast by Type (2017-2022)
Figure EMEA RNA Interference (RNAi) Drug Delivery Sales Market Share Forecast by Type (2017-2022)
Table EMEA RNA Interference (RNAi) Drug Delivery Sales (K Units) Forecast by Application (2017-2022)
Figure EMEA RNA Interference (RNAi) Drug Delivery Sales Market Share Forecast by Application (2017-2022)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources